Evaluation of any steroid sparing effect of beta blocker therapy on airway hyper-responsiveness in stable, mild to moderate, asthmatics. - Beta Blocker Therapy in Mild to Moderate Asthmatics ANDA1

Tayside Clinical Trials Unit, University of Dundee0 个研究点开始时间: 2011年12月20日最近更新: 2013年6月17日

适应症

试验速览

暂无简介。

•Male and female volunteers age 18-65 with stable mild to moderate asthma. Histamine PC20 <8mg/ml. Steroid naïve or receiving inhaled steroid up to 1000µg/day BDP equivalent dose +/- long acting beta agonist(LABA) or leukotriene receptor antagonist. Stable defined as: FEV1 >60% predicted; diurnal FEV1 variability <30% when LABA washed out; reliever use =8puffs/day.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 0
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range 0

•Uncontrolled symptoms of asthma; Resting systolic BP<110mmHg or resting HR<60bpm; Pregnancy or lactation; Known or suspected sensitivity to IMP; Inability to comply with protocol; Any degree of heart block; Rate-limiting medication including beta blockers, rate-limiting Calcium Channel Blockers and Amiodarone; Any clinically significant medical condition that may endanger the health or safety of the participant, or jeopardise the protocol; An asthma exacerbation requiring systemic steroids within 6 months of study commencement; Has not participated in another study in the previous 30 days.

发起方

Tayside Clinical Trials Unit, University of Dundee